Mualliflar

  • Саидова Ш.А., Зуфаров П.С., Мовлонова З.Н.

##semicolon##

дапаглифлозин, стеатоз печени, сахарный диабет 2 типа, МАЖБП, параметр контролируемого затухания, жесткость печени, жировая болезнь печени.

##submission.citations##

1. Wu JY, Chang HY, Tsung Y, Lin YM. Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM. Diabetes Res Clin Pract. 2025; 229:112918. doi:10.1016/j.diabres.2025.112918

2. Surma S, Bułdak Ł. Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD) - pathogenesis, prevention and treatment. Front Endocrinol. 2025; 16:1703019. doi:10.3389/ fendo.2025.1703019

3. Suki M, Imam A, Amer J, et al. SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals. 2025;18(8):1118. doi:10.3390/ph180 81118

4. Moncho F, Benlloch S, Górriz JL. The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Clin Kidney J. 2025;18(9):sfaf260. doi:10.1093/ckj/ sfaf260

5. Lin J, Huang Y, Xu B, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo-controlled trial. BMJ. 2025;389:e083735. doi:10.1136/bmj-2024-083735

6. Ge Q, Zhang F, Liu Y. Effect of SGLT2 inhibitors on liver fat content: A meta-analysis. Biomol Biomed. 2025;25(12):2647-2657. doi:10.17305/bb.20 25.12203

7. Abdel Monem MS, Adel A, Abbassi MM, et al. Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial. Clin Res Hepatol Gastroenterol. 2025;49 (3):102543. doi: 10.1016/j.clinre.2025.102543

8. Ong Lopez AMC, Pajimna JAT. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep. 2024;14(1):2122. doi:10.1038/s41598-024-52603-5

9. Gao X, Zhu C, Zhu W, Wang L. Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes. Biomed Rep. 2024;22(2):26. doi:10.3892 /br.2024.1904

10. Konings LAM, Miguelañez‐Matute L, Boeren AMP, et al. Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review. Eur J Clin Invest. 2025; 55(4): e70003. doi:10.1111/eci.70003

11. Cheong AJY, Teo YN, Teo YH, et al. SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials. Obesity. 2022;30 (1):117-128. doi:10.1002/oby.23331

12. Liu Y, Chen Y, Ma J, et al. Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;388:e081820. doi:10.1136/ bmj-2024-081820